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Abstract 
 
The GetReal consortium (“incorporating real-life data into drug development”) addresses the 
efficacy–effectiveness gap that opens between the data from well-controlled randomized trials in 
selected patient groups submitted to regulators and the real-world evidence on effectiveness and 
safety of drugs required by decision makers. Workpackage 4 of GetReal develops evidence synthesis 
and modelling approaches to generate the real-world evidence. In this commentary, we discuss how 
questions change when moving from the well-controlled randomized trial setting to real-life medical 
practice, the evidence required to answer these questions, the populations to which estimates will 
be applicable to and the methods and data sources used to produce these estimates. We then 
introduce the methodological reviews written by GetReal authors and published in Research 
Synthesis Methods on network meta-analysis, individual patient data meta-analysis and 
mathematical modelling to predict drug effectiveness. The critical reviews of key methods are a 
good starting point for the ambitious programme of work GetReal has embarked on. The different 
strands of work under way in GetReal have great potential to contribute to making clinical trials 
research as relevant as it can be to patients, caregivers and policy makers.  
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The randomized clinical trial is the most reliable study design to determine the efficacy and safety of 
drugs. However, the clinical trials system has been described as “broken,” “in crisis” and “not fit for 
purpose”: many trials do not achieve patient enrolment targets; spiralling costs and complex 
regulatory and monitoring requirements prevent the conduct of others; and many completed trials 
do not answer clinically relevant questions or are not applicable to everyday medical practice but are 
driven by commercial considerations (DeVita, 2008; Vickers, 2014; Loudon et al., 2013). As a 
consequence, fewer trials that are relevant to patients, caregivers and policy makers are carried out, 
and the evidence on the benefits and risks of drugs is becoming less reliable.  
Several initiatives have been established in recent years to remedy this situation. In the USA, Duke 
University and the Food and Drug Administration established CTTI, the Clinical Trials Transformation 
Initiative (Tenaerts et al., 2014). CTTI’s mission is “to promote practices that will increase the quality 
and efficiency of linical trials, ”with the aim to create a clinical trials system that is “patient centered 
and efficient, enabling reliable and timely access to evidence-based prevention and treatment 
options.” The initiative has generated evidence and formulated recommendations, for example, to 
streamline risk-based trial monitoring and the ethical review process. Similarly, Oxford University in 
the UK, McMaster University in Canada and Duke have joined forces to form the Sensible Guidelines 
Group to “rid clinical trials of undue bureaucracy, maximize patient safety, and improve the 
efficiency of reaching valid conclusions from large multi-centre randomized studies” (Shurlock, 
2013). 
Launched in October 2013, “GetReal: Incorporating real-life data into drug development” of the 
European Union’s Innovative Medicines Initiative is another important development to enhance the 
efficiency of randomized trials and the quantification of effectiveness and safety of drugs in real-
world medical practice. GetReal is a public–private consortium consisting of academia, 
pharmaceutical companies, health technology assessment agencies, regulators and patient 
organizations (GetReal consortium, 2016). GetReal addresses the “efficacy–effectiveness gap” 
(Eichler et al., 2011) that opens between the data from well-controlled randomized studies in 
selected patient groups submitted to regulators and the real-world evidence (RWE) on effectiveness 
and safety of drugs, required by decision makers. Decisions on whether a new drug should be made 
available in a national health system or reimbursed by social insurance requires evidence on its 
relative effectiveness and safety compared with established treatments and the wider implications 
including costs of introducing a new therapy. Ideally, such evidence should be made available to 
regulatory and health technology assessment agencies before the drug enters the market. 
GetReal aims to develop methods and tools that support the generation of RWE on the relative 
effectiveness of new drugs that could inform decision-making before the drug is launched. The 
GetReal consortium works with stakeholders to (i) develop a framework for the acceptability of RWE 
for estimating the effectiveness of new medicines (workpackage 1), (ii) study the scientific validity of 
RWE, including non-randomized study designs, and analytical approaches and drivers of 
effectiveness (workpackage 2), (iii) examine the challenges and possible solutions to performing 
pragmatic trials earlier in the development process, in particular prelaunch or peri-launch 
(workpackage 3), (iv) develop evidence synthesis and modelling approaches to generate RWE, based 
on combination of both randomized and observational study data (workpackage 4) Workpackage 4 
will be of particular interest to the readership of Research Synthesis Methods.  
In workpackage 4, we examine how estimates of the relative efficacy of drugs in clinical trial 
populations, their relative effectiveness in real world populations and their relative effectiveness in 
the real world of a healthcare systems can best be obtained, using data from phase II/III clinical trials 
and from real-world clinical databases and registries. Table 1 summarizes the questions asked, 
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moving from the randomized clinical trial setting to real-life medical practice, the evidence required 
to answer these questions, the populations to which estimates will be applicable to and the methods 
and data sources used to produce these estimates. 
We use case studies of the treatment of chronic diseases, for example, schizophrenia, depression 
and rheumatoid arthritis, to examine different methodological approaches for combining both 
randomized and observational study data, both using aggregate study data and using individual 
participant data. For example, we use network meta-analysis approaches of aggregate study results 
to obtain estimates of relative efficacy from several randomized trials. One of the drugs in the 
network is, for the sake of the argument, designated as the “new kid on the block,” and the trials of 
this drug are assumed to be prelaunch, whereas the other drugs are assumed to be on the market. 
Subsequently, individual participant data (IPD) provided by the participating pharmaceutical 
companies and observational data from clinical databases and disease registries are combined to 
identify important factors that modify the drug’s relative effectiveness and to estimate its 
performance in patient populations that will likely receive the drug after launch. Of note, at this 
stage, the relative effectiveness of the drug continues to be estimated under randomized study 
conditions, rather than real-world conditions (Table 1). 
For example, adherence to treatments is implicitly assumed to correspond to that observed in the 
phase II/III trials. The next step is to account for the messy real world, where doctors decide who will 
receive the new drug, influenced by guidelines, patient characteristics and preferences, and other 
factors. In order to gauge relative effectiveness, these decisions need to be understood as well as 
the possible confounding factors that may be associated with the probability both of receiving the 
drug and of developing the outcome and the variables that may be associated with the treatment 
(but not with the outcomes) or of variables associated with outcomes (but not treatment). The likely 
adherence to the new drug and to the comparator drugs is also relevant. Empirical evidence on 
these factors will typically be scarce, or absent. Drawing directed acyclic graphs and in-depth 
discussions with clinicians are helpful to understand how the different variables are likely to interact 
and what predictive model might be most appropriate (Westreich and Edwards, 2015). 
It is good practice first to critically review the methods and applications that will be important in a 
research programme, to gain an understanding of the relevant strengths and limitations. In this issue 
and a previous issue of the journal, GetReal investigators present reviews of common methods used 
for network meta-analysis (Efthimiou et al., 2016), IPD meta-analysis (Debray et al., 2015) and 
mathematical modelling to predict drug effectiveness (Panayidou et al., 2016). In their review of 
network meta-analysis methods, Efthimiou et al. summarize the key issues involved, including novel 
methods for measuring and detecting inconsistency in the network, dealing with effect modification, 
ways for adjusting for possible sources of bias and the reporting of the results of a network meta-
analysis (Efthimiou et al., 2016). IPD meta-analysis is widely considered to be the gold standard in 
meta-analytic research, but in their review, Debray et al. stress that they are no panacea to the 
limitations of the included studies. Also, IPD meta-analyses are major undertakings, which cannot be 
performed ad hoc or on a shoe string, and their potential advantages, for example, the powerful 
investigation of interaction and subgroup effects, must be carefully weighed against the extra efforts 
involved (Debray et al., 2015). Finally, Panayidou and colleagues comprehensively searched for 
studies that predicted real-world effectiveness from randomized controlled trial data. Of note, they 
found only 12 articles and four modelling approaches, mainly Markov multistate models (Panayidou 
et al., 2016). Although most studies included sensitivity analyses, external validation was rarely 
performed. 
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The critical reviews of the key methodologies published in the Research Synthesis Methods are a 
good starting point for the ambitious programme of work the GetReal consortium has embarked on. 
The different strands of work under way in GetReal have great potential to contribute to making 
clinical trials research as relevant as it can possibly be to patients, caregivers and policy makers. 
 
 
 
Table 1. From efficacy to relative effectiveness in the real world.  
 
Steps and 
questions 
Outcomes 
of interest 
Applicability 
to patient 
populations 
Data sources Methodology Conditions 
1) How efﬁcacious Efﬁcacy, Typical patients Phase II/III Clinical trials, Study 
and safe is this safety included in clinical randomised standard conditions 
drug? 
 
 trials clinical trials meta-analysis  
2) How efﬁcacious Relative Typical patients Phase II/III Network Study 
and safe is this efﬁcacy, included in clinical randomised meta-analysis conditions 
drug compared relative safety trials clinical trials   
with alternative      
therapies? 
 
     
3) How effective Relative Patients predicted to Phase II/III Individual Study 
and safe is this effectiveness, receive the drug post- randomised patient data conditions 
drug compared relative safety launch clinical trials, network  
with alternative in predicted  clinical databases meta-analysis  
therapies, in study  and registries and meta-  
patients who will populations   regression  
likely receive it      
post-launch? 
 
     
4) How effective Relative Patients predicted to Phase II/III Mathematical Real-world 
and safe is this effectiveness, receive the drug post- randomised modelling conditions 
drug compared relative safety launch in a given clinical trials,   
with alternative in predicted healthcare system clinical databases   
therapies, in the real-world  and registries,   
patients who will populations  expert opinion,   
likely receive it in   patient   
the real world of a   preferences   
healthcare      
system? 
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